Here, we report the first preclinical validation of the postulated gemcitabine-sensitizing effect of GHR antagonism using two different GHRAs in cultured pancreatic cancer cells and mouse tumor xenografts. This evidence concerns the gene GHR and familial pancreatic carcinoma.